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Summary Human colon adenocarcinoma cells (LoVo) resistant to the new antitumor agent FCE 24517
[benzoyl-mustard derivative of distamycin A] (LoVo/24517) are resistant to the selecting agent and related
molecules as well as to vinblastine, with marginal or no resistance to other antitumour drugs. Treatment with
verapamil, tamoxifen, nicergoline or cyclosporin A only partially restores the activity of FCE 24517 against
LoVo/24517 cells. Such results suggest that resistance mechanisms possible specific for this class ofcompounds
are operating.
FCE 24517, a benzoyl-mustard derivative of the antiviral
agent distamycin A (Arcamone et al., 1989; Kopka et al.,
1985), is a novel antitumour compound currently being inves-
tigated in phase I clinical trials (Figure 1).
The mechanism of action responsible for the antitumour
activity of this compound remains to be established. Like
distamycin A, FCE 24517 binds preferentially to adenine-
thymine rich sequences in the minor groove ofP-DNA (Brog-
gini et al., 1991). Both compounds inhibit the binding of
transcription factors which recognise adenine-thymine rich
boxes, but have no effects on the guanine-cytosine rich ones
(Broggini et al., 1989; 1991). It was reported that FCE 24517
directly and specifically inhibits human DNA ligase (Monte-
cucco et al., 1991). This effect is not shared by distamycin A.
The parent compound distamycin A has a very low cytotoxic
activity and is inactive as an antitumour agent; the insertion
of the alkylating benzoyl-mustard moiety on the distamycin
A skeleton confers to FCE 24517 a potent antiproliferative
activity in vitro and antineoplastic activity in vivo against a
variety of experimental tumours of both murine and human
origin (Pezzoni et al., 1991).
Despite the fact that FCE 24517 contains an alkylating
moiety, its mode of action appears to be different from that
of classical alkylating agents. It was recently reported that, in
contrast with the alkylating agents currently used, FCE
24517 does not alkylate guanine N7 but only adenine N3
(Broggini et al., 1991).
When dealing with novel antitumour compounds, the
availability of resistant cell sublines is of the utmost impor-
tance for obtaining information as to their mode of action, as
well as identifying the resistance pattern that can emerge
after treatment. For this purpose, we have isolated a human
colon adenocarcinoma cell line selected after repeated in vitro
treatment with FCE 24517 (LoVo/24517). All the charac-
terisation experiments with this cell line have been carried
out in comparison with the doxorubicin (DX) resistant cell
line, LoVo/Dx. LoVo/DX cells, selected and characterised in
our laboratory (Grandi et al., 1986), present the classical
multidrug resistant (MDR) phenotype, with overexpression
of mdr-l mRNA and DNA (Ballinari et al., 1988) and strong
positivity of monoclonal antibodies directed against p170
(Dinota et al., 1990). Since the cytotoxic activity of FCE
24517 was markedly reduced against LoVo/DX cells, com-
pared with the parent line (Pezzoni et al., 1991), it was
anticipated that treatment with this compound would also
select a MDR population.
To test this possibility, the following parameters have been
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Figure 1 Chemical structure of distamycin A, FCE 24517, FCE
26366 and FCE 25217.
investigated in the LoVo/24517 and LoVo/DX cell lines: (i)
mdr-J mRNA expression; (ii) patterns of cross-resistance to
other anticancer drugs; and (iii) influence of the addition of
verapamil, tamoxifen, cyclosporin A or nicergoline, known
modulators of MDR (Rogan et al., 1984; Ramu et al., 1984;
Meador et al., 1987; Carfagna & Rossi, 1989) on the cytotox-
icity of FCE 24517 or DX.
The results reported here seem to indicate that the resis-
tance to FCE 24517 in LoVo cells is only partially mediated
by mdr-J-pl70.
Materials and methods
Drugs
FCE 24517, FCE 25217, FCE 26366, doxorubicin and nicer-
goline were from Farmitalia Carlo Erba (Milan, Italy); vin-
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blastine was from Eli Lilly (Indianapolis, USA); melphalan
and camptothecin were from Sigma Chemical Co. (St Louis,
USA); 5-fluorouracil was from Roche SpA (Milan, Italy);
BCNU was from Simes SpA (Vicenza, Italy); cisplatin and
VP-16 were from Bristol Myers Lab. (Syracuse, NY, USA);
mAMSA was from Drug Synthesis and Chemistry Branch,
DCT, NCI (Bethesda, USA); tamoxifen was from ICI
Pharma (Milan, Italy); cyclosporin A was from Sandoz
(Basel, Switzerland) and verapamil was from Knoll AG,
Knoll Farmaceutici (Milan, Italy).
Cell lines
The human colon adenocarcinoma cell line, LoVo (Drewinko
et al., 1976), its sublines resistant to FCE 24517, LoVo/
24517, and to doxorubicin, LoVo/DX (Grandi et al., 1986)
were maintained in Ham's F12 medium (GIBCO, Grand
Island Biological Co., Grand Island, NY, USA) supplement-
ed with 10% foetal bovine serum (Flow Laboratories, UK),
1% vitamins (vitamins BME solution, 100 x, GIBCO) and
1% L-glutamine 200 mM (GIBCO).
LoVo/24517 cells were maintained in the absence of FCE
24517 and LoVo/DX cells in the presence of DX (100 ng
ml-').
Growth rate
Doubling times were evaluated. Cells at a concentration of
15,000 cellscm2 were seeded into 16mm plastic wells (Fal-
con; Becton Dickinson, Milan, Italy). Cell growth was
monitored daily for 10 days by counting the cells with a ZM
Coulter Counter (Coulter Electronics Ltd, Northwell Drive,
Luton, Beds, LU3 3RH, UK) beginning 24 h after plating
and doubling times calculated.
Cytotoxicity
Cells were seeded in 35 mm plastic dishes at a concentration
of 600 cells per dish; after 48 h cells were treated with the
drugs for 4 h, then medium was replaced with fresh medium,
and colonies were counted after 8-10 days using an optical
microscope.
The concentration inhibiting 50% colonies growth (IC50)
was calculated from dose-response curves and expressed as
ng ml-1.
mdr-mRNA expression
Total cellular RNA was extracted by the guanidium isothio-
cyanate/cesium chloride centrifugation method (Maniatis et
al., 1982).
For Northern blot analysis 20 tg of total RNA was frac-
tionated on 1% agarose gel containing 6.7% formaldehyde
and transferred to nylon membranes (Gene-screen plus, New
England Nuclear). The filters were hybridised for 16 h at
42°C in 50% formamide, 10% dextran sulfate, 1 M NaCI, 1%
SDS (Sodium Dodecyl Sulfate), 100Ogml-' of denatured
salmon sperm DNA and 106cpmml1' of denatured 32p_
labelled probe. After hybridisation the filters were washed
sequentially in 2 x SSC (0.15 M Sodium Chloride and
0.015 M sodium citrate) at room temperature and in 2 x SSC
1% SDS at 65°C. The probes utilised were the 1.3 kb EcoRI/
SalI insert of pcDR.3 (Gros et al., 1986) containing the
human mdr-J gene (Gros et al., 1986) and the 1.8 kb PstI
insert of the murine actin gene. Both probes were 32P-labelled
using the multiprime DNA labeling system and 32P-dCTP
(Amersham, UK).
The autoradiographic signals for mdr-J expression were
quantitated using an image analyser IBAS 2 (Kontron
Electronic GHBH pc 386 MS-DOS) and the values were
normalised with those obtained for a-actin.
Results
Development ofdrug resistance
LoVo cells were treated continuously with FCE 24517 at
increasing-doses of 50 (six passages), 100 (30 passages), 200
(35 passages) ng per ml, after which the subline LoVo/24517
was established and found to express an approximate 50-fold
order of resistance (see Table I). This resistance index (RI)
was unchanged after >50 passages without the drug.
Data reported refer to LoVo/24517 cells maintained with-
out drug, although equivalent results were also obtained
using cells maintained in 200 ng per ml of FCE 24517 (data
not shown).
Biological characteristics ofLoVo/24517 cells
During 96 h of culture, the three cell lines have similar
growth rates with a lag-phase of 24 h and a doubling time of
25 h.
The plating efficiencies were similar being 39, 41 and 50%
for LoVo, LoVo/24517 and LoVo/DX cells, respectively.
mdr-1 mRNA expression
The levels of mdr-J mRNA expression in the three cell lines
are shown in Figure 2.
Assessment by image analysis, indicated a 24-fold higher
level of mdr-J mRNA expression in the LoVo/DX cells than
in the LoVo cells, whilst only a 2-fold increase was noted in
the LoVo/24517 cells.
Patterns ofresistance to different antitumour drugs
Data in Table I show that LoVo/24517 cells were most
resistant to the selecting agent with RI = 56.3 and show cross
resistance to only one of the mdr-associated drugs, vinblas-
tine (RI = 25.5) with marginal or no cross resistance being
observed to DX, VP-16 or mAMSA, with RI = 4.3, 2.4, 1.8
respectively. These data contrast with results obtained using
LoVo/DX cells, which showed cross resistance to all these
mdr-associated drugs, as well as to FCE 24517.
Among the other drugs tested, both resistant cell lines
retained full sensitivity to cisplatin, melphalan, BCNU, 5-
fluorouracil and to camptothecin, but cross resistance was
observed to the FCE 24517 related compounds FCE 25217
(RI = 53) and FCE 26366 (RI = 11.8).
Effect ofresistance modulators
Table II presents the results obtained assaying the effect of
treatment with four resistance modulating agents (RMAs), at
their highest non-cytotoxic doses on the activity of the FCE
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Figure 2 Northern blot analysis of mdr-J mRNA expression,
LoVo (line 1); LoVo/24517 (line 2); LoVo/DX (line 3). The filter
was subsequently hybridised to actin probe to normalise the
amount of RNA loaded in each line.918 L. CAPOLONGO et al.
Table I Cytotoxic activity of different antitumour drugs against LoVo, LoVo/24517 and LoVo/DX
cells
Cytotoxicity (IC50 = ng ml-])a
Compounds LoVo LoVo/24517 LoVo/DX
FCE 24517 66±9 3717±388 (56.3)b 2211±372 (33.5)b
Doxorubicin 103±4 440±4 (4.3) 5886±475 (57.0)
Vinblastine 56±9 1430± 134 (25.5) 15933±830 (284.5)
VP-16 1523±206 3600±497 (2.4) 160000±33925 (105.0)
m-AMSA 50±25 89± 13 (1.8) 1200±505 (24.0)
Cisplatin 723± 159 1400± 167 (1.9) 680± 171 (0.9)
Melphalan 957±47 1700±254 (1.8) 1583±249 (1.7)
BCNU 6750± 152 10000±372 (1.5) 7250±252 (1.1)
5-Fluorouracil 15267± 1158 10200±749 (0.7) 19433±745 (1.3)
Camptothecin 27±6 22±7 (0.8) 27±7 (1.0)
FCE 25217 4±2 212±41 (53.0) 142±20 (35.5)
FCE 26366 14200± 1645 167500± 12627 (11.8) 109000± 11112 (7.7)
Colony assay - 4h treatment. aIC50±s.e. =concentration inhibiting 50% of colony formation+
standard error. bIn parenthesis RI = resistance index = IC50 resistant subline 1C50 parental line
Table II Reversing effect of verapamil, nicergoline, tamoxifen and cyclosporin A on
resistance to FCE 24517 and doxorubicin in LoVo/24517 and LoVo/DX cells
LoVo/24517 LoVo/DX
Compounds IC50a Rt IC50a Rt
(ngml-') (ng ml-')
FCE 24517 - 3500±600 51.5 2531±319 37.2
FCE 24517 +Verapamil 20figml- 1030±9 15.1 222±53 3.3
FCE 24517 +Nicergoline 12fgml-' 1560± 109 22.9 116±16 1.7
FCE 24517 +Tamoxifen 1Iofgml-, 980± 137 14.4 156±25 2.3
FCE 24517 +Cyclosporin A10 Lgml' 730± 135 10.7 187±22 2.8
DX - 510±44 4.3 6055±582 50.5
DX +Verapamil 20fig ml- 223±41 1.9 340±94 2.8
DX +Nicergoline 12 tg ml-' 332±39 2.8 453± 83 3.8
DX +Tamoxifen lOtiLgml' 129±40 1.1 330±74 2.8
DX +Cyclosporin A10ltgml ' 113±23 1.0 230±20 1.9
Colony assay - 4 h treatment. aIC50+s.e. = concentration inhibiting 50% of colony
formation±standard error: FCE 24517 LoVo = 68 ng ml '+6; DX LoVo = 120 ngml-'±+ 12.
bRI = resistance*ind
- IC50 resistant subline bRI = resistance index = IC50 parental line
24517 and DX on LoVo/24517 or LoVo/DX cells. Testing
LoVo/24517 cells, the activity of FCE 24517 is only partially
restored by the addition of each RMA. Conversely, a com-
plete restoration of FCE 24517 cytotoxic activity was
obtained testing LoVo/DX cells; the RI being reduced from
37.2 to 3.3-1.7. In both cell lines however, resistance to DX
was completely restored after treatment with these RMAs:
the marginal resistance observed in LoVo/24517 cells (RI =
4.3) being reduced to 1-2.8; whilst in LoVo/DX cells, the RI
is reduced from 50.5 to 1.9-3.8.
Discussion
The fact that the cytotoxic activity of FCE 24517, a benzoyl-
mustard derivative of distamycin A whose mode of action is
not yet elucidated, was markedly reduced against MDR cells
(Pezzoni et al., 1991) suggests that this novel structure is
recognised by a p170-mediated extrusion mechanism. How-
ever, this paper demonstrates that exposure of LoVo cells to
FCE 24517 does not select for the 'classical' p170-mediated
mechanism of resistance.
A 56.3-fold FCE 24517 resistant subline (LoVo/24517)
proved 25.5-fold resistant to vinblastine, but only marginally
or no resistant to DX, VP-16 and to mAMSA and mdr-J
mRNA expression was only elevated 2-fold. In apparent
contrast, the classic LoVo/DX subline proved cross resistant
to all these mdr-associated drugs and showed a 24-fold
overexpression of mdr-J mRNA, but this subline also proved
33-fold cross resistant to FCE 24517. Indeed, both LoVo/
24517 and LoVo/DX cells also showed cross resistance to the
other distamycin A analogues tested.
Similar results have also been observed in the murine
leukaemia L1210 cell line (Geroni et al., 1993).
RMAs also had differential effects on the LoVo/24517 and
LoVo/DX cells, proving more effective in modulating FCE
24517 cytotoxicity in the latter as opposed to the former
subline. Conversely in combination with DX, the four RMAs
were effective in completely restoring activity in both cell
lines. Taken together, these data indicate that resistance
selected after treatment with FCE 24517 in these LoVo sub-
lines, can be only partially mediated through p170 overex-
pression.
The main mode of action, therefore, remains to be esta-
blished and these LoVo sublines will prove valuable in these
mechanistic studies.
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